Progenics Pharma (PGNX) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Progenics (PGNX) PT Lifted at Needham & Company on Relistor Tailwinds, Expanded Imaging Pipeline
August 6, 2015 1:20 PM EDTNeedham & Company analyst Chad Messer raised sales estimates and his price target on Buy-rated Progenics Pharmaceuticals (NASDAQ: PGNX) to $11.00 (from $9.00) citing Relistor tailwinds and expanded imaging pipeline.
Messer commented, "We are increasing our sales estimates for Relistor (and thus our PGNX price... More
